Skip to content

Statera Biopharma, Inc.: 10-Q filed 2017-08-14

What Statera Biopharma, Inc. reported in its quarterly report filed 2017-08-14 (fiscal Q2 2017): 26 published measures, 73 facts as tagged in accession 0001318641-17-000037.

This filing

Form
10-Q (quarterly report)
Filed
2017-08-14
Fiscal period
fiscal Q2 2017
Accession
0001318641-17-000037 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Statera Biopharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-3012,230,951USD
At 2016-12-3115,955,870USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-06-302,359,512USD
At 2016-12-313,109,089USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-06-304,607,157USD
At 2016-12-317,523,970USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-303,932,001USD
At 2016-12-316,901,816USD
At 2016-06-305,412,067USD
At 2015-12-315,918,424USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-5,612,788USD91
2017-01-01 to 2017-06-30-7,276,482USD181
2016-04-01 to 2016-06-30-1,897,868USD91
2016-01-01 to 2016-06-30-2,565,804USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-158,016,638USD
At 2016-12-31-150,740,156USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-04-01 to 2017-06-300USD91
2017-01-01 to 2017-06-300USD181
2016-01-01 to 2016-06-300USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-06-3023,599USD
At 2016-12-3137,376USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-1,570,512USD91
2017-01-01 to 2017-06-30-3,189,960USD181
2016-04-01 to 2016-06-30-1,494,249USD91
2016-01-01 to 2016-06-30-3,806,555USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-3012,176,733USD
At 2016-12-3115,887,941USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-302,359,512USD
At 2016-12-313,109,089USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-06-30298,280USD
At 2016-12-31336,435USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-06-30427,184USD
At 2016-12-31352,700USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-04-01 to 2017-06-301,776,668USD91
2017-01-01 to 2017-06-303,971,090USD181
2016-04-01 to 2016-06-302,069,274USD91
2016-01-01 to 2016-06-305,194,080USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2017-06-301,188,380USD91
2017-01-01 to 2017-06-302,605,378USD181
2016-04-01 to 2016-06-301,292,167USD91
2016-01-01 to 2016-06-303,233,407USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-3011,279,834shares
At 2016-12-3110,987,166shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-06-30-539,000USD
At 2016-12-31-564,559USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2017-06-309,871,439USD
At 2016-12-3112,846,781USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-06-3030,619USD
At 2016-12-3130,553USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-06-301,200,216USD
At 2016-12-311,823,235USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-5,648,142USD91
2017-01-01 to 2017-06-30-7,348,229USD181
2016-04-01 to 2016-06-30-1,886,341USD91
2016-01-01 to 2016-06-30-2,557,083USD182

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-5,654,207USD91
2017-01-01 to 2017-06-30-7,250,923USD181
2016-04-01 to 2016-06-30-1,892,665USD91
2016-01-01 to 2016-06-30-2,560,446USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30588,288USD91
2017-01-01 to 2017-06-301,365,712USD181
2016-04-01 to 2016-06-30777,107USD91
2016-01-01 to 2016-06-301,960,673USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2017-01-01 to 2017-06-3011,641USD181
2016-01-01 to 2016-06-3041,565USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2017-04-01 to 2017-06-3050,434USD91
2017-01-01 to 2017-06-3099,723USD181
2016-04-01 to 2016-06-30121,969USD91
2016-01-01 to 2016-06-30303,734USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-4,077,630USD91
2017-01-01 to 2017-06-30-4,158,269USD181
2016-04-01 to 2016-06-30-392,092USD91
2016-01-01 to 2016-06-301,249,472USD182

Inspect the source

Entity
Statera Biopharma, Inc. / CIK 0001318641
Captured
SEC response SHA-256
9e499247f86d1cf9ca87ba87bfcdf37d42baa7907f4baa6e983f1992a49045f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001318641.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))